News

UnitedHealth Group (NYSE:UNH), a major provider of health insurance and healtchare services, closed Tuesday at $282.69, down 19.61%. The stock sold off after  Q4 results showed plunging operational

In this video, I will cover UnitedHealth Group's (NYSE: UNH) recent quarterly results and explain why the stock tanked. Watch the short video to learn more, consider subscribing, and click the

Looking to beat the market over the next five years? Here's one strategy to adopt: Invest in stocks that have not performed well recently but boast attractive prospects.

Two intriguing corporations

Shares of health insurance giant UnitedHealth Group (NYSE: UNH) stock imploded this morning, falling 19% through 11 a.m. ET after reporting Q4 earnings. The weird thing is... UnitedHealth didn't

The healthcare sector lagged broader equities last year. Novo Nordisk (NYSE: NVO) and Merck (NYSE: MRK), two pharmaceutical leaders, were among the underperformers. But here's the good news: There

Monday was generally a good day for the stock market; nevertheless, some titles landed in negative territory. One that plunged well into the red was clinical-stage biotech Revolution Medicines

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label

It's tough to be a value investor. For much of the past 15 years, the market environment has featured growth stocks that appear to be very expensive by most conventional value metrics. Even though

Leading tech companies continue to report insatiable demand for artificial intelligence (AI). This is driving tremendous investment in chips, data centers, and cloud platforms. The AI market is

Pharmaceutical giant Eli Lilly (NYSE: LLY) and biotech Viking Therapeutics (NASDAQ: VKTX) have one major thing in common: They both work in the high-growth area of weight loss drugs. Lilly's

Abbott Laboratories (NYSE: ABT) announced its 2025 fourth-quarter and full-year results before the market opened on Thursday, Jan. 22, 2026. And its shares promptly plunged nearly 10%. As you

When you're talking about the biggest stock market stories of 2025, Nvidia (NASDAQ: NVDA) is a name that keeps coming up. The company has been one of the biggest winners of the artificial

The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain

Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) underperformed in 2025. Both companies encountered some issues, some of which may linger throughout this year.

However, these drugmakers

On January 23, Liberty Street Advisors disclosed a buy of 136,925 shares of Voyager Technologies (NYSE:VOYG), an estimated $3.71 million trade based on quarterly average pricing.

According to its

Some investors believe the market is currently overvalued. Hype and optimistic expectations, especially for artificial intelligence (AI) stocks, are baked into equity prices, or so the argument

ImmunityBio (NASDAQ:IBRX), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

Trading

There are few better, simpler, and more accessible ways to accumulate wealth over the long term than buying and holding shares of outstanding companies. And although it can be challenging to find

On January 22, 2026, Premier Path Wealth Partners, LLC disclosed a purchase of 64,073 shares of iShares Trust - iShares MSCI ACWI ex U.S. ETF (NASDAQ:ACWX), an estimated $4.25 million trade based on

If you had only $30 to spend on a single share of a company, which one would you choose? Although price and value aren't the same thing on equity markets, the best stocks tend to attract enough

Although investors have been told that spending on artificial intelligence (AI) is going to ramp up again in 2026, some are getting a bit weary of the AI trade. However, they must realize that this

Zoetis (NYSE: ZTS) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two healthcare leaders that have lagged broader equities over the past 12 months, as both encountered headwinds that led to

It's been a less-than-thrilling past few months for investors in Palantir Technologies (NASDAQ: PLTR), but understandably so. Shares of the artificial intelligence software powerhouse remain